Download NICE Expands Positive Recommendation for Erbitux as First

News Release
Your Contact
Gangolf Schrimpf
+49 6151 72-9591
Not intended for UK- or US-based media
March 2, 2017
NICE Expands Positive Recommendation for Erbitux
as First-line Treatment for RAS Wild-type mCRC
•
More patients now able to receive a standard-of-care treatment with
Erbitux plus FOLFIRI or FOLFOX
•
NICE’s recommendation is a significant step forward in Merck’s
aspiration to ensure cancer patients have optimal access to effective
treatments worldwide
Darmstadt, Germany, March 2, 2017 – Merck, a leading science and technology
company, announced today that the UK National Institute for Health and Care
Excellence (NICE) has issued a positive Final Appraisal Determination (FAD)
recommending the routine National Health Service (NHS) use of Erbitux®
(cetuximab) in combination with either FOLFIRI or FOLFOX as a first-line treatment
for patients with RAS wild-type metastatic colorectal cancer (mCRC). Erbitux has
long been established and reimbursed as a first-line standard-of-care treatment
option in most European countries and many other countries worldwide.
“The NICE decision is great news for patients and their families in England, as it now
means they will have access to this effective first-line treatment,” said Maya
Martinez-Davis, Global Head of Oncology Franchise for the biopharma business of
Merck. “Our efforts in working with NICE to reach this important milestone are part
of our relentless commitment to bringing tailored, effective therapies to patients
worldwide.”
This decision expands the previous NICE recommendation,1 which endorsed the use
of Erbitux in combination with either FOLFOX or FOLFIRI solely for patients whose
cancer had spread only to the liver (liver-limited disease). It is based on robust data
Page 1 of 3
Frankfurter Strasse 250
64293 Darmstadt · Germany
Hotline +49 6151 72-5000
www.merckgroup.com
Head Media Relations -62445
Spokesperson: -9591 / -7144 / -6328
Fax +49 6151 72 3138
[email protected]
News Release
from Phase III clinical studies having demonstrated that Erbitux in combination with
either FOLFIRI2,3,4 or FOLFOX,2,5,6 as a first-line treatment for patients with RAS wildtype mCRC, confers significant benefit in patient outcomes.
“Patients with metastatic colorectal cancer in the UK have very limited access to
effective first-line treatments,” said Jola Gore-Booth, Founder/CEO of the colorectal
cancer patient advocacy group, EuropaColon. “We are therefore delighted with
NICE’s decision, as it means there is now more choice for patients in England
regarding treatment options that they can benefit from.”
Both the European Society for Medical Oncology and the US National Comprehensive
Cancer Network clinical guidelines also recommend first-line treatment with Erbitux,
in combination with either FOLFOX or FOLFIRI, for patients with RAS wild-type
mCRC.7,8
Erbitux has obtained marketing authorization in over 90 countries worldwide. To
date, more than 480,000 patients with mCRC have been treated with Erbitux.
For further information and press materials please visit
www.merckgroup.com/media-center-oncology.
References
1. National Institute for Health and Care Excellence. Cetuximab for the first-line treatment of
metastatic colorectal cancer: TA176. Available from:
https://www.nice.org.uk/guidance/TA176/chapter/1-Guidance. Accessed February 2017.
2. Lenz H et al. Ann Oncol 2014;25(Suppl 5):v1–41.
3. Van Cutsem E et al. J Clin Oncol 2015;33(7):692–700.
4. Stintzing S et al. Oral presentation at the 2014 European Society for Medical Oncology Congress,
September 26–30, 2014. Abstract No:LBA11.
5. Bokemeyer C et al. J Clin Oncol 2014;32:(Suppl 4): abstr 3505.
6. Qin S, et al. Ann Oncol 2016;27(suppl 4):0-025.
7. Van Cutsem E et al. Ann Oncol 2014;25(Suppl 3):iii 1–9.
8. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology (NCCN
Guidelines). Colon Cancer. Version 2.2016. Available from: www.nccn.org/patients. Accessed
February 2017.
9. Vaughn CP et al. Genes Chromosomes Cancer 2011;50(5):307−12.
10. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D,
Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No.
11 [Internet]. Lyon, France: International Agency for Research on Cancer. 2013. Available from:
http://globocan.iarc.fr. Accessed February 2017.
About the NICE process
By publishing a Final Appraisal Determination (FAD), the National Institute for Health and Care Excellence
(NICE) has made final recommendations on how Erbitux with FOLFOX/FOLFIRI should be used in the
NHS. If there are no successful appeals, the final recommendations will be issued as NICE guidance.
Page 2 of 3
News Release
About mCRC
Approximately half of patients with mCRC have RAS wild-type tumors and half have RAS mutant tumors.9
Results from studies assessing RAS mutation status in patients with mCRC have shown that antiepidermal growth factor receptor (EGFR) monoclonal antibody therapies, such as Erbitux® (cetuximab),
can improve outcomes in patients with RAS wild-type mCRC.2-6 Colorectal cancer (CRC) is the third most
common cancer worldwide, with an estimated incidence of more than 1.36 million new cases annually.10
An estimated 694,000 deaths from CRC occur worldwide every year, accounting for 8.5% of all cancer
deaths and making it the fourth most common cause of death from cancer.10 Almost 55% of CRC cases
are diagnosed in developed regions of the world, and incidence and mortality rates are substantially
higher in men than in women.10
About Erbitux
Erbitux® is a highly active IgG1 monoclonal antibody targeting the epidermal growth factor receptor
(EGFR). As a monoclonal antibody, the mode of action of Erbitux is distinct from standard non-selective
chemotherapy treatments in that it specifically targets and binds to the EGFR. This binding inhibits the
activation of the receptor and the subsequent signal-transduction pathway, which results in reducing
both the invasion of normal tissues by tumor cells and the spread of tumors to new sites. It is also
believed to inhibit the ability of tumor cells to repair the damage caused by chemotherapy and
radiotherapy and to inhibit the formation of new blood vessels inside tumors, which appears to lead to
an overall suppression of tumor growth.
The most commonly reported side effect with Erbitux is an acne-like skin rash that seems to be correlated
with a good response to therapy. In approximately 5% of patients, hypersensitivity reactions may occur
during treatment with Erbitux; about half of these reactions are severe.
Erbitux has already obtained market authorization in over 90 countries world-wide for the treatment of
colorectal cancer and for the treatment of squamous cell carcinoma of the head and neck (SCCHN). Merck
licensed the right to market Erbitux outside the US and Canada from ImClone LLC, a wholly-owned
subsidiary of Eli Lilly and Company, in 1998. Merck has an ongoing commitment to the advancement of
oncology treatment and is currently investigating novel therapies in highly targeted areas.
All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck
Website. Please go to www.merckgroup.com/subscribe to register online, change your selection or
discontinue this service.
About Merck
Merck is a leading science and technology company in healthcare, life science and performance materials.
Around 50,000 employees work to further develop technologies that improve and enhance life – from
biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific
research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck
generated sales of €12.85 billion in 66 countries.
Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family
remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the
global rights to the Merck name and brand. The only exceptions are the United States and Canada, where
the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
Page 3 of 3